MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 584159 | Name: Benserazide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Benserazide is an inhibitor of dopa decarboxylase that does not enter the central nervous system. It is often given with levodopa in the treatment of parkinsons to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no anti-parkinsons actions when given alone.

Chemical Structure

Benserazide
Benserazide
CAS#322-35-0

Theoretical Analysis

MedKoo Cat#: 584159

Name: Benserazide

CAS#: 322-35-0

Chemical Formula: C10H15N3O5

Exact Mass: 257.1012

Molecular Weight: 257.24

Elemental Analysis: C, 46.69; H, 5.88; N, 16.33; O, 31.10

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Benserazide; Serazide; Ro 44602; Ro-44602; Ro44602
IUPAC/Chemical Name
DL-Serine, 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide
InChi Key
BNQDCRGUHNALGH-UHFFFAOYSA-N
InChi Code
InChI=1S/C10H15N3O5/c11-6(4-14)10(18)13-12-3-5-1-2-7(15)9(17)8(5)16/h1-2,6,12,14-17H,3-4,11H2,(H,13,18)
SMILES Code
NC(CO)C(NNCC1=CC=C(O)C(O)=C1O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 257.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Wan Y, Wu N, Song L, Wang X, Liu Z, Yuan W, Gan J. Levodopa/Benserazide Loaded Microspheres Alleviate L-dopa Induced Dyskinesia through Preventing the Over-Expression of D1R/Shp-2/ERK1/2 Signaling Pathway in a Rat Model of Parkinson's Disease. Front Aging Neurosci. 2017 Oct 18;9:331. doi: 10.3389/fnagi.2017.00331. eCollection 2017. PubMed PMID: 29093677; PubMed Central PMCID: PMC5651254. 2: Wollmer E, Klein S. Development and Validation of a Robust and Efficient HPLC Method for the Simultaneous Quantification of Levodopa, Carbidopa, Benserazide and Entacapone in Complex Matrices. J Pharm Pharm Sci. 2017;20(0):258-269. doi: 10.18433/J3K923. PubMed PMID: 28810948. 3: Pellegrini C, Antonioli L, Colucci R, Tirotta E, Gentile D, Ippolito C, Segnani C, Levandis G, Cerri S, Blandini F, Barocelli E, Ballabeni V, Bernardini N, Blandizzi C, Fornai M. Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration. Neuropharmacology. 2017 Sep 1;123:22-33. doi: 10.1016/j.neuropharm.2017.05.016. Epub 2017 May 17. PubMed PMID: 28526609. 4: Li W, Zheng M, Wu S, Gao S, Yang M, Li Z, Min Q, Sun W, Chen L, Xiang G, Li H. Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2. J Exp Clin Cancer Res. 2017 Apr 20;36(1):58. doi: 10.1186/s13046-017-0530-4. PubMed PMID: 28427443; PubMed Central PMCID: PMC5399312. 5: Druzhyna N, Szczesny B, Olah G, Módis K, Asimakopoulou A, Pavlidou A, Szoleczky P, Gerö D, Yanagi K, Törö G, López-García I, Myrianthopoulos V, Mikros E, Zatarain JR, Chao C, Papapetropoulos A, Hellmich MR, Szabo C. Screening of a composite library of clinically used drugs and well-characterized pharmacological compounds for cystathionine β-synthase inhibition identifies benserazide as a drug potentially suitable for repurposing for the experimental therapy of colon cancer. Pharmacol Res. 2016 Nov;113(Pt A):18-37. doi: 10.1016/j.phrs.2016.08.016. Epub 2016 Aug 10. PubMed PMID: 27521834; PubMed Central PMCID: PMC5107130. 6: Guo G, Xu S, Cao LD, Wu QY. The effect of levodopa benserazide hydrochloride on homocysteinemia levels in patients with Parkinson's disease and treatment of hyperhomocysteinemia. Eur Rev Med Pharmacol Sci. 2016 Jun;20(11):2409-12. PubMed PMID: 27338068. 7: Alirezaei M. Betaine protects cerebellum from oxidative stress following levodopa and benserazide administration in rats. Iran J Basic Med Sci. 2015 Oct;18(10):950-7. PubMed PMID: 26730328; PubMed Central PMCID: PMC4686578.